Ingrezza is a medication used to treat tardive dyskinesia and chorea associated with Huntington's disease. It is a selective VMAT2 inhibitor [1].
How does Ingrezza work?
Ingrezza works by inhibiting the vesicular monoamine transporter type 2 (VMAT2) in the brain [1]. VMAT2 is responsible for transporting monoamines, such as dopamine, into synaptic vesicles for storage and release. By inhibiting VMAT2, Ingrezza reduces the amount of dopamine available for release in the synapse, which is believed to help alleviate the involuntary movements associated with tardive dyskinesia and Huntington's disease chorea [1].
Who makes Ingrezza?
Ingrezza is manufactured by Neurocrine Biosciences [2].
When did Ingrezza get approved?
Ingrezza received its initial FDA approval in April 2017 for the treatment of tardive dyskinesia [2][3]. It later received approval for chorea associated with Huntington's disease in August 2023 [2].
What is the patent status for Ingrezza?
The patent landscape for Ingrezza is complex, involving multiple patents covering its composition of matter, methods of use, and manufacturing processes. Information on the specific expiration dates and any ongoing patent litigation or challenges can be found on DrugPatentWatch.com [4].
How does Ingrezza compare to other treatments for tardive dyskinesia?
Other treatments for tardive dyskinesia include other VMAT2 inhibitors like Austedo (deutetrabenazine) [5]. Ingrezza is generally taken once daily, while some other medications may require more frequent dosing [1][5]. Clinical studies have shown that Ingrezza significantly reduces the abnormal involuntary movements characteristic of tardive dyskinesia [1].
What are the side effects of Ingrezza?
Common side effects of Ingrezza can include somnolence and oral dryness [1]. Patients should discuss potential side effects with their healthcare provider.
How much does Ingrezza cost?
The cost of Ingrezza can vary based on insurance coverage, pharmacy, and dosage. Information regarding patient assistance programs and typical out-of-pocket costs can often be found through the manufacturer's website or by consulting with a pharmacy.
Can Ingrezza be used for other conditions?
Currently, Ingrezza is approved for tardive dyskinesia and chorea associated with Huntington's disease. Research and clinical trials may explore its potential for other neurological conditions.
---
Sources:
[1] DrugPatentWatch.com
[2] Neurocrine Biosciences
[3] FDA Approves Ingrezza (valbenazine) Capsules, a Novel Treatment for Tardive Dyskinesia
[4] DrugPatentWatch.com
[5] Austedo (deutetrabenazine) Prescribing Information